SCHEMBL16628576

SCHEMBL16628576

CCC(Nc1nc(NCCN)nc(NCCN)n1)([Si](OC(C)=O)(OC(C)=O)OC(C)=O)[Si](OC(C)=O)(OC(C)=O)OC(C)=O

nearest known ligand 0.33

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.33
LMNA P02545 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
MCL1 Q07820 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HTT P42858 1/20 0.30
SYK P43405 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16628616 0.78 KMT2A (0.34) KMT2A
SCHEMBL16628593 0.71 PAOX (0.35) L3MBTL1KMT2AMEN1GAAMCL1
SCHEMBL16628578 0.70 L3MBTL1 (0.33) L3MBTL1LMNAKMT2AMEN1GAA
SCHEMBL16628590 0.70 L3MBTL1 (0.33) L3MBTL1KMT2AMEN1GAAMCL1
SCHEMBL430482 0.66 CXCR4 (0.40) L3MBTL1LMNAKMT2AMEN1GAA
SCHEMBL428279 0.65 CYP1A2 (0.52) L3MBTL1LMNAKMT2AMEN1GAA
SCHEMBL20375134 0.65 CYP1A2 (0.52) L3MBTL1LMNAKMT2AMEN1GAA
SCHEMBL29940880 0.64
SCHEMBL16769809 0.62 CA1 (0.49) KMT2A
SCHEMBL9913709 0.62 CA1 (0.49) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334933-A1 SURFACE TREATMENT AGENT AND NOVEL COMPOUND Mori, Kunio (JP) 2017-11-23 US claimed
US-20150152124-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2015-06-04 US claimed
EP-2859962-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2015-04-15 EP claimed
US-11440304-B2 Laminate and its production method AGC Inc. (JP) 2022-09-13 US disclosed
EP-3505522-B1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND MORI KUNIO (JP) 2020-10-14 EP disclosed
US-20200164625-A1 LAMINATE AND ITS PRODUCTION METHOD AGC Inc. (JP) 2020-05-28 US disclosed
US-10385076-B2 Surface treatment agent and novel compound Mori, Kunio (JP) 2019-08-20 US disclosed
EP-3505522-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2019-07-03 EP disclosed
EP-2859962-B1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND MORI KUNIO (JP) 2019-01-23 EP disclosed
US-20170334933-A1 SURFACE TREATMENT AGENT AND NOVEL COMPOUND Mori, Kunio (JP) 2017-11-23 US disclosed
US-9790242-B2 Surface treatment method, surface treatment agent, and novel compound Mori, Kunio (JP) 2017-10-17 US disclosed
US-20150152124-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2015-06-04 US disclosed
EP-2859962-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2015-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152124-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND EPCAM, ITGAM, MET L3MBTL1 4696/4885LMNA 2695/4885KMT2A 330/4885
US-20170334933-A1 SURFACE TREATMENT AGENT AND NOVEL COMPOUND EPCAM, MET, ITGAM L3MBTL1 4685/4885LMNA 1873/4885KMT2A 502/4885
US-10385076-B2 Surface treatment agent and novel compound EPCAM, MET, ITGAM L3MBTL1 4685/4885LMNA 1873/4885KMT2A 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.